Skip to content

Studying the Levetiracetam effect on controlling chronic Migraine

Studying the Levetiracetam effect on controlling chronic Migraine

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250713066468N1
Enrollment
60
Registered
2025-07-23
Start date
2025-08-23
Completion date
Unknown
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine. Chronic migraine without aura

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive levetiracetam tablets, initially 250 mg every 12 hours in the first week, then increased to 500 mg every 12 hours fr

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with chronic migraine Age over 18 years old

Exclusion criteria

Exclusion criteria: Pregnant women Secondary headaches Renal or hepatic dysfunction Severe psychiatric disorders Malignancies Drug or alcohol use

Design outcomes

Primary

MeasureTime frame
Number of attacks. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Interview.;Severity of attacks. Timepoint: Before and 12 weeks after the intervention. Method of measurement: HIT6 questionnaire.;Duration of attacks. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Interview.

Secondary

MeasureTime frame
Complications (Dizziness, drowsiness). Timepoint: 12 weeks after intervention. Method of measurement: Interview.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Surena Nazarbaghi

Oroumia University of Medical Sciences

nazarbaghi_s@umsu.ac.ir+98 44 3345 7286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026